Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients


Australia-based Kazia Therapeutics Limited KZIA announced final data from a Phase 2 study of paxalisib as first-line therapy in patients with glioblastoma.

  • 60mg once daily was identified as the maximum tolerated dose (MTD) and selected for future studies. 
  • Median overall survival (OS) in the intent-to-treat (ITT) population (n=30) was 15.7 months, which compares very favorably to 12.7 months historically reported with temozolomide in this patient group.
  • Temozolomide is the only existing FDA-approved drug treatment for first-line treatment.
  • Median progression-free survival (PFS) in the ITT population was 8.4 months, representing a substantial increment over the comparable figure of 5.3 months associated with temozolomide. 
  • In the modified ITT (mITT) population, OS increased to 15.9 months.
  • Kazia expects to receive a final clinical study report in 1Q CY2022.
  • Last year, Kazia commenced participation in the GBM AGILE pivotal study. This global trial recruited its first patient to the paxalisib arm in January 2021, and recruitment is ongoing. 
  • Kazia provisionally expects indicative data in CY2023. 
  • Price Action: KZIA shares are down 9.29% at $9.08 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralbrain cancerBrain TumorBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!